Horraantii Maarso, Maamulka Badeecadaha Caafimaadka Qaranka ayaa ansixiyay Jaypirca® (pirtobrutinib) si loogu daaweeyo bukaanada qaangaarka ah ee qaba leukemia lymphocytic chronic (CLL) ama lymphoma yar oo lymphocytic ah (SLL) kuwaas oo helay ugu yaraan hal daaweyn nidaamsan oo hore, oo ay ku jirto daawada Bruton's tyrosine kinase (BTK) inhibitor.
Pirtobrutinib waa daawo kinase ah oo aad loo xushay oo adeegsata hab cusub oo aan isku xidhnayn oo aan isku xidhnayn si loo ballaariyo faa'iidada bartilmaameedsiga waddada BTK ee bukaannada CLL/SLL ee hore loogu daaweeyay daawada BTK ee isku dhafan (ibrutinib, acalabrutinib, ama zanubrutinib). Pirtobrutinib wuxuu ogolaansho ka helay US FDA bishii Janaayo 2023 isagoo ah daawo aan isku xidhnayn (dib loo rogi karo). Bishii Oktoobar 2024, pirtobrutinib waxaa lagu ansixiyay Shiinaha sidii daaweyn hal-hal ah oo loogu talagalay daaweynta bukaannada qaangaarka ah ee qaba lymphoma unugyada mantle ee soo noqnoqda ama dib u dhaca (MCL) kuwaas oo hore u helay ugu yaraan laba daaweyn oo nidaamsan oo hore, oo ay ku jiraan daawada Bruton's tyrosine kinase (BTK) ee ku shaqeysa.
Ansixinta tilmaantan cusub waxay ku salaysan tahay natiijooyinka daraasadda caalamiga ah ee BRUIN CLL 321 ee heerka caalamiga ah, oo xarun badan leh, oo aan kala sooc lahayn. BRUIN CLL 321 waa tijaabadii ugu horreysay ee marxaladda 3aad ee la kala soocay ee adduunka oo lagu sameeyay bukaannada qaba CLL/SLL kuwaas oo hore loogu daaweeyay daawada BTK ee isku-dhafan (cBTKi). Daraasaddu waxay diiwaangelisay wadarta 238 bukaan waxayna qiimeysay waxtarka iyo badbaadada daaweynta pirtobrutinib marka loo eego doorashada baaraha ee IdelaR (idelalisib oo lagu daray rituximab) ama BR (bendamustine oo lagu daray rituximab). Natiijooyinku waxay muujiyeen in pirtobrutinib uu si weyn u dheereeyay badbaadada ka xor ah horumarka dhexdhexaadka ah (PFS) marka la barbar dhigo habka doorashada baaraha (14.0 bilood vs 8.7 bilood; saamiga khatarta [HR] = 0.54). Intaa waxaa dheer, heerka joojinta daawada oo ay ugu wacan tahay dhacdooyinka xun ee la xiriira daaweynta ayaa hoos u dhacay marka la qaato pirtobrutinib (5.2% marka loo eego 21.1%), taasoo sii xoojinaysa waxtarkeeda iyo faa'iidooyinka dulqaadka ee bukaanada hore loogu daaweeyay daawada BTK ee covalent.
Nala Soo Xiriir Si Aad U Bilaabto Safarkaaga Rajada
Waaxda Caalamiga ah ee Isbitaalka Oncology ee Gobolka Koonfureed ee Beijing waxay u heellan tahay inay siiso bukaanada caalamiga ah helitaanka daaweynta kansarka ugu horumarsan. Haddii adiga ama xubin qoyskaaga ka mid ah ay wajahayaan cudurka kansarka oo ay jawaab celin ku filan ka helin daaweynta caadiga ah, kooxdayada Adeegyada Bukaanka Caalamiga ah waxay diyaar u yihiin inay ku siiyaan macluumaad faahfaahsan iyo qorshayaasha daaweynta shaqsiyeed.
Fadlan nala soo xiriir iyada oo loo marayo kanaallada soo socda si aad wax badan uga barato fursadaha daaweynta kansarka:
- Telefoon: 400-880-3716
- WeChat: 17801183037
- Email: 100085_010@163.com or myimmnet@163.com (Emails are welcome, and we will respond promptly)
Waaxda Caalamiga ah ee Isbitaalka Oncology ee Gobolka Koonfureed ee Beijing waxay rajeyneysaa inay kula shaqeyso la dagaallanka kansarka. Meel kasta oo aad adduunka ka joogto, waxaan ka go'an nahay inaan ku siino taageero caafimaad oo xirfad leh iyo daryeel naxariis leh.
Take the first step towards overcoming your illness. Call us at 400-880-3716 or contact us via WeChat at 17801183037 today. You can also email us at 100085_010@163.com or myimmnet@163.com to schedule a one-on-one consultation with our team of experts.
Waqtiga boostada: Maarso-12-2026